Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.3K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.3K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.7K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.7K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep brain stimulation of the anterior thalamic nucleus in Lennox-Gastaut syndrome with EEG changes during off-on stimulation.

Brain stimulation·2026
Same author

Cyclic alternating patterns of encephalopathy: implications for triphasic waves in noncomatose patients with metabolic-toxic encephalopathies.

Critical care (London, England)·2026
Same author

Centroparietal periodic sharp-wave discharges and biphasic complexes: Novel EEG biomarkers for early diagnosis of Rasmussen encephalitis.

Epilepsy & behavior reports·2026
Same author

Charlotte Dravet: Life and contributions to epileptology.

Epilepsia·2026
Same author

Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial.

Epilepsia·2026
Same author

Automated MRI-based atrophy patterns to improve the diagnosis of generalized epilepsies in outpatient care.

Seizure·2026

Related Experiment Video

Updated: Apr 28, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K

Zonisamide for refractory juvenile absence epilepsy.

Reana Velizarova1, Arielle Crespel1, Pierre Genton2

  • 1Epilepsy Unit, Hôpital Gui de Chauliac, Montpellier, France.

Epilepsy Research
|June 8, 2014
PubMed
Summary

Zonisamide (ZNS) effectively treated drug-resistant juvenile absence epilepsy (JAE) in adults, showing broad-spectrum seizure control. This add-on therapy proved efficient and well-tolerated, even at higher dosages.

Keywords:
Absence seizuresAntiepileptic drugsDrug resistanceJuvenile absence epilepsyZonisamide

More Related Videos

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

22.8K
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

5.5K

Related Experiment Videos

Last Updated: Apr 28, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

22.8K
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

5.5K

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Juvenile absence epilepsy (JAE) can be drug-resistant.
  • Zonisamide (ZNS) is an established antiepileptic drug.

Purpose of the Study:

  • To evaluate the clinical effectiveness and safety of zonisamide (ZNS) as an add-on therapy for adult patients with drug-resistant juvenile absence epilepsy (JAE).

Main Methods:

  • An observational, post-marketing study involving 13 adult JAE patients treated with add-on ZNS between 2006 and 2010.
  • Safety and efficacy were assessed via patient and caregiver reports every 3 months.
  • A response was defined as a ≥50% reduction in seizure frequency.

Main Results:

  • All patients experienced a >50% reduction in absence seizures (AS) frequency with add-on ZNS.
  • Five patients (38.5%) achieved seizure freedom, including those with AS only and AS plus generalized tonic-clonic seizures (GTCS).
  • ZNS demonstrated efficacy against AS and showed some effect on GTCS, with no reported absence status complications post-treatment.

Conclusions:

  • Add-on zonisamide is an effective and well-tolerated treatment for drug-resistant juvenile absence epilepsy in adults.
  • Zonisamide exhibits broad-spectrum anticonvulsant activity, including efficacy in absence seizures.
  • The study supports the use of ZNS in refractory JAE, even at high doses.